The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease

NCT01750502 | Completed Results

• 1 other identifier: wenzhouhp
• Study Type: observational
• Target: 256
• Locations: 1 country
• Sites: 1

Brief Summary

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that promote the inflammatory response.In animal studies, it has been found that MIF is released in the ischaemic heart, promoting glucose uptake and protecting the heart from ischaemia-reperfusion injury.The MIF concentration, influenced by age and myocardial ischemia, have different impact on myocardial functional recovery after ischemia.Therefore, the purpose of this experiment is to study the clinical significance of MIF in patients with coronary heart disease.

Conditions

Coronary Heart Disease

Outcome Measures

Primary Outcomes (1)

• Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration

  Participants will be extracted 3ml blood before surgery 5 minutes,detection MIF concentration on two groups.We hypothesis that the experimental group will be higher than control group.

  Before surgery 5 minutes

Secondary Outcomes (1)

• Comparison the Change of MIF Before and After Percutaneous Coronary Intervention （PCI） at the Patients Who Are Acute Coronary Syndromes and Stable Ischemic Heart Disease

  3 times including before surgery 5 minutes, 5 minutes after the opening of the balloon and after surgery 5 minutes

Other Outcomes (2)

• Comparison With MIF-173G/C Genotypes of CHD Patients and Controls.

  Before surgery

• Comparison of MIF-173G/C Alleles of CHD Patients and Controls.

  Before surgery

Study Arms (2)

coronary-artery-disease group

Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.

non-coronary-artery-disease group

Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.

Eligibility Criteria

• Age: 20 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Second Hispital of Wenzhou Medical College outpatient and inpatient

You may qualify if:

• Control group:
• enroll individuals who confirmed by coronary angiography without coronary heart
• The age between 20 and 80 years old.
• Alanine aminotransferase(ALT):10-55U/L, Aspartate aminotransferase(AST):0-60U/L
• Glucose(GLU-S):3.9-6.1mmol/L
• Triglycerides(TRIG):0.56-1.7mmol/L, cholesterol(CHOL):3.1-5.2mmol/L, High density lipoprotein(HDL):0.78-1.96mmol/L, High density lipoprotein(LDL):2.07-3.1mmol/L
• Experimental group:
• enroll individuals who confirmed by coronary angiography for coronary heart
• The age between 20 and 80 years old.
• ALT:10-55U/L,AST:0-60U/L
• GLU-S:3.9-6.1mmol/L
• TRIG:0.56-1.7mmol/L,CHOL:3.1-5.2mmol/L,HDL:0.78-1.96mmol/L,LDL:2.07-3.1mmol/L

You may not qualify if:

• Inflammatory diseases,such as rheumatoid arthritis,sepsis,asthma and acute respiratory distress syndrome.
• Diabetes

Sponsors & Collaborators

• Wenzhou Medical University: lead

Study Sites (1)

Second Hispital of Wenzhou Medical College

Wenzhou, Zhejiang, 325000, China

Location

Related Publications (2)

• Qian L, Wang XY, Thapa S, Tao LY, Wu SZ, Luo GJ, Wang LP, Wang JN, Wang J, Li J, Tang JF, Ji KT. Macrophage migration inhibitory factor promoter polymorphisms (-794 CATT5-8): Relationship with soluble MIF levels in coronary atherosclerotic disease subjects. BMC Cardiovasc Disord. 2017 Jun 2;17(1):144. doi: 10.1186/s12872-017-0570-x.

  PMID: 28578664 DERIVED

• Ji K, Wang X, Li J, Lu Q, Wang G, Xue Y, Zhang S, Qian L, Wu W, Zhu Y, Wang L, Liao L, Tang J. Macrophage migration inhibitory factor polymorphism is associated with susceptibility to inflammatory coronary heart disease. Biomed Res Int. 2015;2015:315174. doi: 10.1155/2015/315174. Epub 2015 Mar 4.

  PMID: 25821795 DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

The biospecimen is blood that taken from cubital vein.

MeSH Terms

Conditions

Coronary Disease

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Limitations and Caveats

There are some limitations to this research. First, the sample size was relative small. Second,no participants were retrospectively analyzed.

Results Point of Contact

• Title: Dr. JiFei Tang
• Organization: Department of Cardiology, the Second Affiliated Hospital, Wenzhou Medical University, Zhejiang province, Wenzhou,China

jiftang@126.com

15968766021

Study Officials

• Jifei Tang, MD

  Wenzhou Medical University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: November 24, 2012
• First Posted: December 17, 2012
• Study Start: May 1, 2012
• Primary Completion: November 1, 2013
• Study Completion: November 1, 2013
• Last Updated: March 4, 2015
• Results First Posted: March 4, 2015

Record last verified: 2015-02

Locations

CN (1)